Cytokinetics | CYTK - Cash And Equivalent

Stock Price
75.85
Daily Change
-2.79 -3.55%
Monthly
15.94%
Yearly
144.68%
Q2 Forecast
74.33

Cytokinetics reported $129.84M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Arca Biopharma USD 49.52M 2.58M Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Biogen USD 3.38B 374.2M Mar/2026
Brainstorm Cell Therapeutics USD 15K 14K Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Capricor Therapeutics USD 105.42M 182.42M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Exelixis USD 226.15M 256.34M Mar/2026
Geron USD 68.9M 10.54M Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025